Ergomed plc Award of Options by CEO to CFO and General Counsel (5759Q)
01 December 2016 - 3:35AM
UK Regulatory
TIDMERGO
RNS Number : 5759Q
Ergomed plc
30 November 2016
PRESS RELEASE
FOR IMMEDIATE RELEASE
Award of options by Chief Executive Officer over personally
owned shares to
Chief Financial Officer and General Counsel
London UK 30 November 2016: Ergomed plc ("Ergomed" or the
"Company", LSE: ERGO), a pharmaceutical services and drug
development company, today announces that Dr Miroslav Reljanović,
founder and Chief Executive Officer of Ergomed, has granted options
over 250,000 ordinary shares from his personal holding to Stephen
Stamp, Chief Financal Officer and Sanja Jurić, General Counsel as
follows:
Name No. Exercise Vesting Resulting Current
of options Price interest shareholding
in options in the Company
------------- ------------ --------- ----------------- ------------ ----------------
Stephen 50% 11 January
Stamp 100,000 GBP0.01 2017 500,000 200,000
50% 11 January
2018
------------- ------------ --------- ----------------- ------------ ----------------
Sanja 50% 30 November
Jurić 150,000 GBP0.01 2016 300,000 NIL
50% 30 November
2017
------------- ------------ --------- ----------------- ------------ ----------------
The 250,000 ordinary shares over which Dr Reljanović has granted
options will remain in his personal holding until exercise. Dr
Reljanović is interested in 17,632,237 ordinary shares of the
Company, representing 43.53% of the issued share capital.
- ENDS -
Enquiries:
Ergomed plc Tel: +44 (0) 1483
503205
Miroslav Reljanovic (Chief Executive
Officer)
Stephen Stamp (Chief Financial
Officer)
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black (Joint Broker)
Stifel Nicolaus Europe Limited Tel: +44 (0) 20
7710 7600
Jonathan Senior (Joint Broker)
FTI Consulting - for UK enquiries Tel: +44 (0) 20
3727 1000
Simon Conway / Mo Noonan
MC Services AG - for Continental Tel: +49 (0) 211
European enquiries 52925222
Anne Hennecke
About Ergomed
Ergomed plc is a profitable UK-based business providing drug
development services to the pharmaceutical industry and has a
growing portfolio of co-development partnerships. It operates in
over 50 countries.
Ergomed provides clinical development, trial management and
pharmacovigilance services to over 100 clients ranging from top 10
pharmaceutical companies to small and mid-sized drug development
companies. Ergomed successfully manages clinical development from
Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular
expertise in oncology, neurology and immunology and the development
of orphan drugs. Ergomed believes its approach to clinical trials
is differentiated from that of other providers by its innovative
Study Site Management model and the use of Study Physician Teams,
resulting in a close relationship between Ergomed and the
physicians involved in clinical trials.
As well as providing high quality clinical development services,
Ergomed is building a portfolio of co-development partnerships with
pharma and biotech companies which share the risks and rewards of
drug development. Ergomed leverages its expertise and services in
return for carried interest in the drugs under development. Lastly,
Ergomed recently acquired a pipeline of proprietary development
products for haemostasis in surgical settings. For further
information, visit: http://ergomedplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUROORNRAAOAA
(END) Dow Jones Newswires
November 30, 2016 11:35 ET (16:35 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024
